These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23252240)

  • 1. [Hepatitis C virus genotype 3: that simple, yet that complex (corrected)].
    Batskikh SN; Morozov SV; Chulanov VP; Pokrovsky VI
    Ter Arkh; 2012; 84(11):4-10. PubMed ID: 23252240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
    Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
    Patton HM; Patel K; Behling C; Bylund D; Blatt LM; Vallée M; Heaton S; Conrad A; Pockros PJ; McHutchison JG
    J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis.
    el-Khattib AA; Abdelhakam SM; Ghoraba DM; Ibrahim WA; Sayed MM
    Eur J Intern Med; 2012 Jan; 23(1):e34-5. PubMed ID: 22153547
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of HCV genetic differences on pathobiology of disease.
    Ripoli M; Pazienza V
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):747-59. PubMed ID: 21905784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors that predict the response to interferon in patients with chronic hepatitis C: clinical management of individual patients.
    Lo Iacono O
    Rev Esp Enferm Dig; 2000 Aug; 92(8):485-94. PubMed ID: 11084816
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ; Lee SD
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in HCV Infection.
    Park SH; Bang CS; Kim DJ
    Adv Clin Chem; 2015; 70():131-96. PubMed ID: 26231487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.
    Liu CJ; Jeng YM; Chen PJ; Lai MY; Yang HC; Huang WL; Kao JH; Chen DS
    Antivir Ther; 2005; 10(3):405-15. PubMed ID: 15918331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
    Tachi Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Samejima Y; Goto H
    Liver Int; 2010 Apr; 30(4):554-9. PubMed ID: 19951380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparing the patient for success: treat or wait?
    Buti M; Esteban R
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S332-6. PubMed ID: 24091112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C and steatosis: a reappraisal.
    Lonardo A; Loria P; Adinolfi LE; Carulli N; Ruggiero G
    J Viral Hepat; 2006 Feb; 13(2):73-80. PubMed ID: 16436124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
    Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
    N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.